Aneurysm: Drug Therapy

Therapeutic target

Prevention of rupture (“rupture”).

Therapy recommendations

Further notes

  • Marfan syndrome: Irbesartan (AT1 -antagonist; dosage: 300 mg per die), with the highest bioavailability (80%) and half-life (11-15 hours) than other sartans, decreased dilatation (widening) of the ascending aorta in a phase III study.Mechanism: blockade of transforming growth factor beta, which is more active in Marfan syndrome. Result: there was an increase of 0.74 mm per year in the placebo group versus irbesartan group 0.53 mm per year in subsequent years (difference of 0.22 mm per year was significant with a 95% confidence interval of 0.02 to 0.41 mm per year).